A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors

This study has been terminated.
(Low rate recruitment)
Sponsor:
Information provided by (Responsible Party):
PharmaMar
ClinicalTrials.gov Identifier:
NCT00404521
First received: November 27, 2006
Last updated: March 25, 2014
Last verified: March 2014
  Purpose

Phase I single-institution, open-label, dose-escalating, clinical and pharmacokinetic study. The purpose is to determine the safety, tolerability and to identify the dose limiting toxicities(DLT) and recommended dose (RD) of PM02734 administered every 3 weeks, intravenously, over 30 minutes to subjects with advanced malignant solid tumors.


Condition Intervention Phase
Solid Tumors
Drug: PM02734
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Single-institution, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM02734 Administered Every 3 Weeks, Intravenously, Over 30 Minutes, to Subjects With Advanced Malignant Solid Tumors.

Resource links provided by NLM:


Further study details as provided by PharmaMar:

Primary Outcome Measures:
  • To determine the safety, tolerability, dose limiting toxicities (DLT) and recommended dose (RD) of PM02734 [ Time Frame: Along the study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To determine preliminary pharmacokinetics, to explore relationships between pharmacokinetics/pharmacodynamics correlation and to evaluate preliminary antitumor activity of PM02734 [ Time Frame: Along the study ] [ Designated as safety issue: No ]

Enrollment: 56
Study Start Date: August 2005
Study Completion Date: May 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: PM02734
Administered every 3 weeks, intravenously, over 30 minutes

Detailed Description:

Phase I single-institution, open-label, dose-escalating, clinical and pharmacokinetic study. The purpose is to determine the safety, tolerability and to identify the dose limiting toxicities(DLT) and recommended dose (RD) of PM02734 administered every 3 weeks, intravenously, over 30 minutes to subjects with advanced malignant solid tumors. Secondary objectives are to determine preliminary Pharmacokinetics of PM02734, to explore the relationships between pharmacokinetics and pharmacodynamics. To evaluate the preliminary pharmacokinetics/pharmacodynamics correlation and to evaluate the preliminary antitumor activity of PM02734. The trial will be conducted in compliance with the protocol, GCP and applicable regulatory requirements.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Voluntary written informed consent of the subject obtained before any study-specific procedure.
  2. Histologically or cytologically confirmed malignant solid tumor.
  3. Subjects with malignancies for which no standard therapy would reasonably be expected to result in cure or palliation.
  4. Age ≥ 18 years.
  5. Subject with measurable or non-measurable disease using the RECIST criteria (only subjects with measurable disease are allowed to enter the expanded cohort).
  6. Recovery from any drug-related adverse event derived from previous treatment, excluding alopecia and NCI-CTCAE grade 1 symptomatic peripheral neuropathy.
  7. Laboratory values within 7 days prior to first infusion:

    • Platelet count ≥ 100 x109/L , hemoglobin > 9 g/dL and absolute neutrophil count (ANC) ≥ 1.5 x109/L.
    • Alkaline phosphatase ≤ 2.5 x the upper limit of normality (ULN) (< 5 x ULN in case of extensive bone metastases).
    • Aspartate aminotransferase (AST): ≤ 2.5 x ULN (<5 x ULN in case of extensive liver metastases).
    • Alanine aminotransferase (ALT): ≤ 2.5 x ULN (<5 x ULN in case of extensive liver metastases).
    • Total bilirubin:1.5 ≤ ULN, unless due to Gilbert's syndrome.
    • Creatinine: ≤ ULN, or measured creatinine clearance: ≥ 60 mL/min without significant proteinuria (>250 mg/m2 /day)
    • Albumin ≥ 2.5 g/dL.
    • Partial thromboplastin time ≤ 1.1 x ULN
    • INR ≤ 1.1
  8. Performance status (ECOG) ≤ 2 .
  9. Life expectancy ≥ 3 months.
  10. Left ventricular ejection fraction (LVEF) within normal limits.
  11. Women of childbearing potential must have a negative serum pregnancy test before study entry. Both men and women must agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months after discontinuation of treatment. Acceptable methods of contraception include complete abstinence, IUD, oral contraceptive, subdermal implant and double barrier (condom with a contraceptive sponge or contraceptive suppository).

Exclusion Criteria:

  1. Prior therapy with PM02734.
  2. Pregnant or lactating women.
  3. Less than 4 weeks from radiation therapy (8 weeks in case of extensive prior radiotherapy) or last dose of hormonal therapy, biological therapy or chemotherapy (6 weeks in case of nitrosourea, mitomycin C, or high-dose chemotherapy).
  4. Evidence of progressive CNS metastases or any symptomatic brain or leptomeningeal metastases.
  5. Evidence of extensive liver metastases ( more than 5 hepatic nodules and some of them greater than 5 cm in diameter)
  6. Other relevant diseases or adverse clinical conditions:

    • Increased cardiac risk: congestive heart failure or unstable angor pectoris or arrhythmia requiring treatment or uncontrolled arterial hypertension or myocardial infarction within 12 months before inclusion in the study.
    • History of significant neurological or psychiatric disorders.
    • Active infection.
    • Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis).
    • Significant non-neoplastic renal disease.
    • Immunocompromised subjects, including subjects known to be infected by human immunodeficiency virus (HIV).
    • Uncontrolled endocrine diseases (e.g. diabetes mellitus, hypothyroidism or hyperthyroidism, adrenal disorder) (i.e. requiring relevant changes in medication within the last month or hospital admission within the last 3 months).
    • Any other major illness that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in this study.
  7. Limitation of the subject's ability to comply with the treatment or to follow-up at a participating protocol. Subjects registered on this trial must be treated and followed at a participating center.
  8. Treatment with ongoing anti-coagulation.
  9. Treatment with any investigational product in the 30 days period prior to the first infusion.
  10. Known hypersensitivity to any of the components of the drug product.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00404521

Locations
United States, Illinois
Cancer Research Center. University of Chicago Hospitals
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
PharmaMar
Investigators
Principal Investigator: Mark Ratain, MD Cancer Research Centerr, University of Chicago Hospital
  More Information

No publications provided

Responsible Party: PharmaMar
ClinicalTrials.gov Identifier: NCT00404521     History of Changes
Other Study ID Numbers: PM2734-A-001-05
Study First Received: November 27, 2006
Last Updated: March 25, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by PharmaMar:
Tumor
PM02734
PharmaMar

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on July 23, 2014